KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Colgate Palmolive (CL) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Colgate Palmolive (CL) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Colgate Palmolive's Cash & Equivalents rose 364.67% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 364.67%. This contributed to the annual value of $1.1 billion for FY2024, which is 1345.76% up from last year.
  • Latest data reveals that Colgate Palmolive reported Cash & Equivalents of $1.3 billion as of Q3 2025, which was up 364.67% from $1.2 billion recorded in Q2 2025.
  • Colgate Palmolive's Cash & Equivalents' 5-year high stood at $1.3 billion during Q3 2025, with a 5-year trough of $775.0 million in Q4 2022.
  • Its 5-year average for Cash & Equivalents is $994.6 million, with a median of $958.0 million in 2021.
  • Per our database at Business Quant, Colgate Palmolive's Cash & Equivalents tumbled by 1185.93% in 2022 and then soared by 3553.11% in 2024.
  • Over the past 5 years, Colgate Palmolive's Cash & Equivalents (Quarter) stood at $832.0 million in 2021, then decreased by 6.85% to $775.0 million in 2022, then grew by 24.65% to $966.0 million in 2023, then increased by 13.46% to $1.1 billion in 2024, then grew by 16.7% to $1.3 billion in 2025.
  • Its Cash & Equivalents was $1.3 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.1 billion in Q1 2025.